Utah Collaborative Pharmacy Practice Agreement

According to health researcher Karen E. Koch, the first initiative of “collaborative management of drug therapy” can be attributed to William A. Zellmers in 1995 in the American Journal of Health-System Pharmacy. [4] Zellmer argues for the use of the term “collaborative management of drug therapy” instead of “prescription,” and argues that this will make laws that expand the authority of pharmacists tastier for legislators (and physician representatives). The most important is the debate on why pharmacists are interested in extending this authority: improving patient care through interdisciplinary cooperation. [5] The modern concept of collaborative practice has been partly derived from the controversial notion of dependent prescribing authority. [4] This toolkit was developed by ChangeLab Solutions, the Centers for Disease Control and Prevention (CDC), the National Alliance of State Pharmacy Associations (NASPA) and the American Pharmacists Association (APhA) as part of a cooperation agreement with ChangeLab Solutions. Under the CAPP, a certified pharmacist-clinician is authorized to register for a personal AED (Drug Enforcement Administration). His field of activity is mainly general medicine and therapeutics.

Currently, they have a normative authority for these three types of disease status: high cholesterol, diabetes and hypertension in specific disease management protocols. [47] The CDTM is an extension of the traditional practice of pharmacists that allows for pharmacist-managed management of drug-related problems (DOP), with a focus on a collaborative and interdisciplinary approach to pharmacy practice in the health field. The conditions of a CPA are defined by the pharmacist and the cooperating physician, although models exist online. CPAs may be specific to a patient population of interest to both parties, a specific clinical situation or disease, and/or a factual protocol for managing the drug treatment of patients under CPA. CPAs have been the subject of intensive debate in pharmacy and medicine. CPAs are a lobbying priority for professional pharmacy organizations. In January 2012, the American Pharmacists Association (APhA) brought together a consortium of pharmacy, medical and care professionals from 12 countries to discuss the integration of CPAs into daily clinical practice. [53] The consortium published a white paper entitled “Consortium Recommendations for Advancing Pharmacists” Patients Care Services and Collaborative Practice Agreements and summarized their recommendations. [18] For pharmacists, I think you have reached one of the few crossroads that will determine the future of your profession.